Johnson & Johnson-Partnered Addex Therapeutics" Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks

Shares of Johnson & Johnson gained 1.7% in premarket trading on Thursday, the day after a study published in the New England Journal of Medicine showed that its COVID-19 vaccine candidate generated neutral.....»»

Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are advancing strongly Tuesday following the release of the results of a late-stage study of its drug candidate for allergic conjunctivitis. Latest R.....»»

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with adjusted EPS surpassing expectations. read more.....»»

read more.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study......»»

The "Mad Money" host is convinced Johnson & Johnson's Covid-19 vaccine efforts will "make you wish you owned a travel and leisure stock.".....»»

Shares of Karyopharm Therapeutics Inc. soared 65% in trading on Monday after the drugmaker said an experimental combination treatment for multiple myeloma met its primary endpoint in a late-stage clinical tria.....»»

Shares of Proteostasis Therapeutics Inc. fell 35% in premarket trading on Tuesday after the biopharmaceutical company shared mixed findings from a mid-stage study for its experi.....»»

Shares of Fate Therapeutics gained 37% after it shared promising data from one clinical and one preclinical study for its experimental cancer immunotherapy treatments. The company is testing two therapies, FT516 and FT500, in.....»»

Shares of Sage Therapeutics Inc. plummeted 59% toward a 2-year low to pace all premarket decliners Thursday, after th.....»»

Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a thinly traded micro-cap biotech, plummeted Tuesday morning. read more.....»»

CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat. .....»»

Phase Bio's stock price was up more than double in premarket trading Monday morning after the Malvern biopharmaceutical company published positive early-stage study results from one of its lead new drug candidate over the weekend The company's stock.....»»

vTv Therapeutics Fails Late-Stage Alzheimer"s Study; Is There A Chance For A Comeback?.....»»

Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis. Idera Pharmaceuticals Inc IDRA announced that the phase II clinical study, eva.....»»

Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV. GlaxoSmithKline’s GSK HIV drug subsidiary-ViiV H.....»»

Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline ca.....»»

Histogenics Corp (NASDAQ: HSGX) shares were losing more than half their market value Wednesday following the release of top-line data from the Phase 3 trial of Neocar read more.....»»

J&J's (JNJ) late-stage candidate, esketamine nasal spray, fails to show sta.....»»